
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
The positive outlook for Compass Pathways PLC is supported by a 95% probability of success for its proprietary COMP360 psilocybin therapy, bolstered by favorable regulatory trends and positive clinical trial results. The recent data from the COMP005 study demonstrates a statistically significant -3.6-point placebo-adjusted reduction on the MADRS scale, which highlights the potential efficacy of COMP360 in treating treatment-resistant depression (TRD). Furthermore, the anticipated low-frequency dosing of COMP360, requiring only 2–4 sessions annually compared to existing therapies, positions the company advantageously within the competitive landscape of mental health treatments.
Bears say
Compass Pathways PLC is currently facing a challenging financial landscape, underscored by its substantial cash burn due to higher-than-expected research and development expenses for the COMP360 Phase 3 clinical trials, resulting in a decrease in cash reserves to $221.9 million as of June 30. Additionally, the company may encounter competitive pressures if rivals produce compelling data in the mental health treatment space, which could adversely affect its stock performance. Furthermore, a lowered discount rate of 18.5% indicates diminishing expectations regarding the successful rollout of COMP360 amidst a burgeoning ketamine treatment market, highlighting further strategic and financial vulnerabilities for the firm.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares